Sorich MJ - Search Results

1

Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.

Karapetis CS, Liu H, Sorich MJ, Pederson LD, Van Cutsem E, Maughan T, Douillard JY, O'Callaghan CJ, Jonker D, Bokemeyer C, Sobrero A, Cremolini C, Chibaudel B, Zalcberg J, Adams R, Buyse M, Peeters M, Yoshino T, de Gramont A, Shi Q. Karapetis CS, et al. Among authors: sorich mj. Br J Cancer. 2024 May;130(8):1269-1278. doi: 10.1038/s41416-024-02604-y. Epub 2024 Feb 24. Br J Cancer. 2024. PMID: 38402342 Free PMC article. Clinical Trial.

2

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Sorich MJ, et al. Ann Oncol. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378. Epub 2014 Aug 12. Ann Oncol. 2015. PMID: 25115304 Free article. Review.

3

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.

Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ. Rowland A, et al. Among authors: sorich mj. Br J Cancer. 2015 Jun 9;112(12):1888-94. doi: 10.1038/bjc.2015.173. Epub 2015 May 19. Br J Cancer. 2015. PMID: 25989278 Free PMC article. Review.

4

Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'.

Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ. Rowland A, et al. Among authors: sorich mj. Br J Cancer. 2015 Dec 1;113(11):1635. doi: 10.1038/bjc.2015.325. Epub 2015 Sep 10. Br J Cancer. 2015. PMID: 26355231 Free PMC article. No abstract available.

5

Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.

Sorich MJ, Kichenadasse G, Rowland A, Woodman RJ, Mangoni AA. Sorich MJ, et al. Int J Cancer. 2016 May 1;138(9):2293-9. doi: 10.1002/ijc.29972. Epub 2016 Jan 6. Int J Cancer. 2016. PMID: 26685869 Clinical Trial.

6

Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.

Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ. Rowland A, et al. Among authors: sorich mj. Eur J Cancer. 2016 Mar;55:122-30. doi: 10.1016/j.ejca.2015.11.025. Epub 2016 Jan 23. Eur J Cancer. 2016. PMID: 26812186 Review.

7

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.

Sorich MJ, Rowland A, Kichenadasse G, Woodman RJ, Mangoni AA. Sorich MJ, et al. Br J Cancer. 2016 Jun 14;114(12):1313-7. doi: 10.1038/bjc.2016.147. Epub 2016 May 26. Br J Cancer. 2016. PMID: 27228299 Free PMC article. Clinical Trial.

8

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.

Hopkins AM, Rowland A, Kichenadasse G, Wiese MD, Gurney H, McKinnon RA, Karapetis CS, Sorich MJ. Hopkins AM, et al. Among authors: sorich mj. Br J Cancer. 2017 Sep 26;117(7):913-920. doi: 10.1038/bjc.2017.274. Epub 2017 Aug 24. Br J Cancer. 2017. PMID: 28950287 Free PMC article. Review.

9

The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.

Prasanna T, Karapetis CS, Roder D, Tie J, Padbury R, Price T, Wong R, Shapiro J, Nott L, Lee M, Chua YJ, Craft P, Piantadosi C, Sorich M, Gibbs P, Yip D. Prasanna T, et al. Acta Oncol. 2018 Nov;57(11):1438-1444. doi: 10.1080/0284186X.2018.1487581. Epub 2018 Jul 23. Acta Oncol. 2018. PMID: 30035653

10

Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials.

Hopkins AM, Nguyen AM, Karapetis CS, Rowland A, Sorich MJ. Hopkins AM, et al. Among authors: sorich mj. Cancers (Basel). 2018 Oct 15;10(10):384. doi: 10.3390/cancers10100384. Cancers (Basel). 2018. PMID: 30326638 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

187 results

Search Page

Filters